| 321.17 Delayed Data As of Feb 21 |  -13.99 / -4.17%Today’s Change | 249.17 Today|||52-Week Range 388.67 | +6.73% Year-to-Date |
| AbbVie's RA Candidate Upadacitinib Gets FDA Priority Review Feb 20 / Zacks.com - Paid Partner Content | The Zacks Analyst Blog Highlights: Visa, Charter, Biogen, BP and BB&T Feb 11 / Zacks.com - Paid Partner Content |
| Alkermes (ALKS) Q4 Earnings & Revenues Surpass Estimates Feb 15 / Zacks.com - Paid Partner Content | Top Research Reports for Visa, Charter Communications & Biogen Feb 08 / Zacks.com - Paid Partner Content |
| Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings Feb 14 / Zacks.com - Paid Partner Content |
| Previous close | 335.16 |
| Today’s open | 329.97 |
| Day’s range | 320.39 - 331.49 |
| Volume | 1,441,537 |
| Average volume (3 months) | 1,360,976 |
| Market cap | $65.4B |
| Earnings growth (last year) | +3.38% |
| Earnings growth (this year) | +9.77% |
| Earnings growth (next 5 years) | +7.70% |
| Revenue growth (last year) | +9.67% |
| P/E ratio | 14.9 |
| Price/Sales | 5.13 |
| Price/Book | 5.03 |
| Today’s change | Today’s % change | |
|---|---|---|
| ILMNIllumina Inc | -5.36 | -1.77% |
| GILDGilead Sciences | -1.43 | -2.13% |
| TLRYTilray Inc | -1.90 | -2.34% |
| NBIXNeurocrine Bioscienc... | -2.05 | -2.58% |
| Next reporting date | April 23, 2019 |
| EPS forecast (this quarter) | $6.92 |
| Annual revenue (last year) | $12.1B |
| Annual profit (last year) | $4.4B |
| Net profit margin | 36.76% |
Sector Health Technology |
Industry Biotechnology |
Chief Executive Officer & Director Michel Vounatsos |
Chief Financial Officer & Executive Vice President Jeffrey D. Capello |
Corporate headquarters Cambridge, Massachusetts |
